MedTrace Logo

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

NCT03554486 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2021-08-18

Study results available
· View outcomes & findings →

Summary

This is a pilot outpatient study conducted at Stanford to obtain preliminary data on how Fiasp® works in a closed-loop system and to determine if any changes need to be made to the 670G pump to optimize the use of Fiasp®.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Fiasp

Fiasp insulin will be used for 2 weeks with the 670G hybrid closed-loop system

DRUG

Novolog

Novolog insulin will be used for 2 weeks with the 670G hybrid closed-loop system

Sponsors & Collaborators

Principal Investigators

  • Bruce Buckingham, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-23
Primary Completion
2019-03-30
Completion
2019-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03554486 on ClinicalTrials.gov